Gaxos.ai adds $2.6M ATM stock capacity
Gaxos.ai Inc. is offering up to an additional $2,600,000 of common stock under its at-the-market Sales Agreement with H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gaxos.ai Inc. is offering up to an additional $2,600,000 of common stock under its at-the-market Sales Agreement with H.C. Wainwright & Co.
The company previously sold 1,515,700 shares for gross proceeds of approximately $3,000,000 under this agreement. As of February 3, 2026, it had 8,639,153 shares outstanding and a public float of 8,416,721 shares valued at about $16,833,442 at $2.00 per share. Under Form S-3 General Instruction I.B.6, it may offer shares with an aggregate offering price of up to approximately $2,611,395.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Gaxos.ai (GXAI) disclose in this 424B5 prospectus supplement?
How much additional common stock can Gaxos.ai (GXAI) sell under the ATM program?
How much has Gaxos.ai (GXAI) already raised through the Sales Agreement?
How does Form S-3 General Instruction I.B.6 limit Gaxos.ai’s offering size?
On which exchange is Gaxos.ai (GXAI) listed and what was the recent price?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-283758
PROSPECTUS SUPPLEMENT
(To Prospectus dated December 18, 2024
To Prospectus Supplement dated January 23, 2026)
Up to $2,600,000
Common Stock
Gaxos.ai Inc.
This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus, dated December 18, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-283758), as supplemented by our prospectus supplement dated January 23, 2026 (collectively, the “Prior Prospectus”). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.
We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, dated January 23, 2026 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, (the “Sales Agent” or “Wainwright”), acting as the agent, and us.
Since our entry into the Sales Agreement, we have offered and sold 1,515,700 shares of common stock for gross proceeds of approximately $3,000,000 million pursuant to the Sales Agreement.
We are filing this Prospectus Supplement to supplement the Prior Prospectus to increase the aggregate amount we intend to sell pursuant to the Sales Agreement. As of the date of this Prospectus Supplement, we are offering up to an additional aggregate of $2,600,000 of our common stock for sale under the Sales Agreement, not including the shares of common stock previously sold pursuant to the Sales Agreement.
Our common stock is listed on the Nasdaq Capital Market under the symbol “GXAI.” On February 3, 2026, the last reported sale price of our common stock was $2.00 per share.
As of the date of this prospectus supplement, the aggregate market value of our common stock held by non-affiliates of our public float was approximately $16,833,442 based on a total number of 8,639,153 shares of common stock outstanding, of which 8,416,721 shares of common stock were held by non-affiliates, at a price of $2.00 per share, the closing sales price of our common stock on February 3, 2026, which is the highest closing price of our common stock on Nasdaq Capital Market within the prior 60 days. We have sold approximately $3,000,000 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement (excluding this offering). Accordingly, based on the foregoing, we are currently eligible under General Instruction I.B.6 of Form S-3 to offer and sell shares of our Common Stock having an aggregate offering price of up to approximately $2,611,395. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is February 4, 2026